Abstract: The present invention is directed to methods of enhancing toxicity of a glycolytic dependent compound towards a cancerous tissue and/or organ in a subject, the method being comprised of targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with the cancerous tissue and/or organ, and administering the glycolytic dependent compound to the subject by a systemic route.

Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.

Abstract: A pyridino-2,16-dioxapentacyclo[7.7.5.01,21.03,8.010,15]henicosa3(8),10,12,14-tetraene-7,20-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Glycan Composites and methods for rendering glycan composites for the treatment of photosynthetic organisms, including the steps of formulating branched glycan deglycosylates into coordination complex compositions resulting in water-borne availability; stability during storage; applying a suitable volume of the resulting mixture to one or more photosynthetic organisms; delivery to photosynthetic organisms; metabolically based growth of crops; enhanced qualities and increased quantities of crops; and systems and compositions for the same.

Abstract: The present disclosure provides floating gastroretentive compositions comprising a multilayer core comprising 1) a pull layer containing liothyronine or a pharmaceutically acceptable salt thereof, an acid, and a gas-generating agent; and 2) a push layer. Each of the pull layer and the push layer comprises a swellable water-soluble hydrophilic polymer. The composition further comprises a permeable elastic membrane covering at least a portion of the multilayer core and containing at least one orifice in fluid communication with the pull layer. The permeable elastic membrane comprises a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride. The composition provides sustained release of liothyronine or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: A composition comprising an insulin-polymer conjugate and an insulin aptamer-glucagon conjugate is described. Depending upon the amount of insulin in the environment surrounding the composition, the insulin aptamer of the insulin aptamer-glucagon conjugate can bind to insulin in the insulin-polymer conjugate to form a non-covalent conjugate. When the amount of insulin in the surrounding environment rises, the insulin aptamer-glucagon conjugate can be released. Thus, the composition can be used to deliver glucagon in an insulin responsive manner. The composition can be loaded into microneedles, for example, to prepare microneedle arrays for skin patches. Methods of delivering glucagon to a subject are also described.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: A composition and method for treating lice and removing nits from human hair, the composition including an alcohol; an inorganic salt in an amount less than 10 wt %; one or more essential oils and/or plant essences; and purified water. The composition may optionally include a surfactant to reduce separation of the ingredients of the composition and increase the appearance of homogeneity within the composition. The method may include applying the composition to human hair and the scalp and combing the hair to remove the lice and nits.

Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection caused by varicella zoster virus and vaccinating the patient prior to administration of an S1P receptor modulator or agonist.

Abstract: An oral delivery system based on in situ forming protein/polysaccharide coacervates is described herein. The system comprises an uncoacervated, dry homogenous mixture comprising a protein powder, a polysaccharide powder, and an active ingredient dispersed therein, wherein the polysaccharide powder has a Carr compressibility index greater than 25% to enable the protein and polysaccharide powders to form a protein/polysaccharide complex coacervate in situ upon immersion of the oral delivery system in a gastric fluid, thereby conferring gastric protection and/or modified release to the active ingredient.

Abstract: A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.

Abstract: The invention relates generally to antimicrobial compositions that are non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The antimicrobial compositions contain at least one zinc compound that is microbicidal to at least one microorganism. The antimicrobial compositions of the invention can be diluted in suitable proportions into suitable solvents to produce the desired dosages for each individual application. The antimicrobial compositions can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like. The compositions can also be used as preservatives. The antimicrobial compositions can also be made as gels or solids in different forms by using techniques available to those skilled in the art.

Abstract: The present invention provides a pharmaceutical composition comprising (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy) phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidinyl-2-yl)-acrylamide or a pharmacologically acceptable salt thereof, which is obtained by mixing the quinoline derivative or a pharmacologically acceptable salt thereof, a wetting agent, a disintegrant, and at least one pharmaceutical excipient; granulating; dynamic drying; and optionally compressing into tablets or filling into capsules after mixing with a lubricant.

Abstract: The present disclosure relates to the field of antimicrobial compositions. More particularly, it concerns the use of a composition as an antimicrobial agent, the composition comprising ingredients selected from the group consisting of: (i) nona-2,6-dien-1-ol in combination with at least one ingredient selected from the group consisting of 3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and 2-isopropyl-5-methylphenol; (ii) gamma-dodecalactone in combination with at least one ingredient selected from the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii) (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv) cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v) 1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein the ingredients are present in an amount sufficient to provide an antimicrobial effect.

Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse. Repeated use of the wipes over time can result in statistically significant improvement in intravaginal ejaculatory latency time (IELT).

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: The invention provides cyclodextrin inclusion complex delivery vehicles formulated for oral delivery, in which the cyclodextrin inclusion complex comprising N-acetylcysteine and acetaminophen as stacked guest molecules within the cyclodextrin cavity is provided together with an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases N-acetylcysteine and acetaminophen from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.

Abstract: Liquid formulations containing picosulfate and magnesium citrate are provided. The compositions can include one or more precipitation inhibitors such as carboxylic acids (e.g., malonic acid), soluble anionic polymers and ammonium salts. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.